Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...